JP5469595B2 - 第Ｘａ因子阻害薬として作用する化合物との併用抗凝固療法 - Google Patents

第Ｘａ因子阻害薬として作用する化合物との併用抗凝固療法 Download PDF

Info

Publication number
JP5469595B2
JP5469595B2 JP2010503078A JP2010503078A JP5469595B2 JP 5469595 B2 JP5469595 B2 JP 5469595B2 JP 2010503078 A JP2010503078 A JP 2010503078A JP 2010503078 A JP2010503078 A JP 2010503078A JP 5469595 B2 JP5469595 B2 JP 5469595B2
Authority
JP
Japan
Prior art keywords
therapeutic agent
compound
drug
group
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2010503078A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010523679A5 (enExample
JP2010523679A (ja
Inventor
ユマ シナー，
スタンリー ジェイ． ホーレンバッハ，
パトリック アンドレ，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Millennium Pharmaceuticals Inc
Original Assignee
Millennium Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharmaceuticals Inc filed Critical Millennium Pharmaceuticals Inc
Publication of JP2010523679A publication Critical patent/JP2010523679A/ja
Publication of JP2010523679A5 publication Critical patent/JP2010523679A5/ja
Application granted granted Critical
Publication of JP5469595B2 publication Critical patent/JP5469595B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4465—Non condensed piperidines, e.g. piperocaine only substituted in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2010503078A 2007-04-13 2008-04-11 第Ｘａ因子阻害薬として作用する化合物との併用抗凝固療法 Expired - Fee Related JP5469595B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US91185207P 2007-04-13 2007-04-13
US60/911,852 2007-04-13
PCT/US2008/004760 WO2008127682A2 (en) 2007-04-13 2008-04-11 Combination anticoagulant therapy with a compound that acts as a factor xa inhibitor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013127495A Division JP2013177459A (ja) 2007-04-13 2013-06-18 第Ｘａ因子阻害薬として作用する化合物との併用抗凝固療法

Publications (3)

Publication Number Publication Date
JP2010523679A JP2010523679A (ja) 2010-07-15
JP2010523679A5 JP2010523679A5 (enExample) 2012-05-17
JP5469595B2 true JP5469595B2 (ja) 2014-04-16

Family

ID=39638994

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2010503078A Expired - Fee Related JP5469595B2 (ja) 2007-04-13 2008-04-11 第Ｘａ因子阻害薬として作用する化合物との併用抗凝固療法
JP2013127495A Pending JP2013177459A (ja) 2007-04-13 2013-06-18 第Ｘａ因子阻害薬として作用する化合物との併用抗凝固療法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2013127495A Pending JP2013177459A (ja) 2007-04-13 2013-06-18 第Ｘａ因子阻害薬として作用する化合物との併用抗凝固療法

Country Status (16)

Country Link
US (3) US20080254036A1 (enExample)
EP (2) EP2155195B1 (enExample)
JP (2) JP5469595B2 (enExample)
KR (1) KR101473207B1 (enExample)
CN (2) CN103071154A (enExample)
AU (1) AU2008239659B2 (enExample)
BR (1) BRPI0809655B8 (enExample)
CA (1) CA2683793C (enExample)
DO (1) DOP2009000244A (enExample)
EA (1) EA020531B1 (enExample)
GT (1) GT200900260A (enExample)
IL (1) IL201433A (enExample)
MX (1) MX2009010953A (enExample)
NZ (1) NZ580162A (enExample)
TN (1) TN2009000408A1 (enExample)
WO (1) WO2008127682A2 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6376515B2 (en) * 2000-02-29 2002-04-23 Cor Therapeutics, Inc. Benzamides and related inhibitors of factor Xa
US7696352B2 (en) * 2004-06-18 2010-04-13 Millennium Pharmaceuticals, Inc. Factor Xa inhibitors
US7521470B2 (en) * 2004-06-18 2009-04-21 Millennium Pharmaceuticals, Inc. Factor Xa inhibitors
WO2007112367A2 (en) * 2006-03-27 2007-10-04 Portola Pharmaceuticals, Inc. Potassium channel modulators and platelet procoagulant activity
EP2016072B1 (en) * 2006-05-05 2014-07-16 Millennium Pharmaceuticals, Inc. Factor xa inhibitors
CN101595092B (zh) 2006-11-02 2012-02-01 米伦纽姆医药公司 合成因子xa抑制剂的医药盐的方法
JP2010515691A (ja) * 2007-01-05 2010-05-13 ミレニアム・ファーマシューティカルズ・インコーポレイテッド 第Ｘａ因子阻害剤
KR101509829B1 (ko) * 2007-05-02 2015-04-06 포톨라 파마슈티컬스, 인코포레이티드 혈소판 ａｄｐ 수용체 억제제로 작용하는 화합물을 이용한 병용요법
US9427448B2 (en) 2009-11-11 2016-08-30 The Medicines Company Methods of treating, reducing the incidence of, and/or preventing ischemic events
US10376532B2 (en) 2009-11-11 2019-08-13 Chiesi Farmaceutici, S.P.A. Methods of treating, reducing the incidence of, and/or preventing ischemic events
HRP20200445T1 (hr) 2009-11-11 2020-06-12 Chiesi Farmaceutici S.P.A. Metode liječenja ili prevencije tromboze u stentu
WO2011075602A1 (en) * 2009-12-17 2011-06-23 Millennium Pharmaceuticals, Inc. Methods of preparing factor xa inhibitors and salts thereof
CN104774176A (zh) 2009-12-17 2015-07-15 米伦纽姆医药公司 合成Xa因子抑制剂的方法
CA2784921A1 (en) 2009-12-17 2011-07-14 Millennium Pharmaceuticals, Inc. Salts and crystalline forms of a factor xa inhibitor
US8663661B2 (en) * 2009-12-23 2014-03-04 Ratiopharm Gmbh Solid pharmaceutical dosage form of ticagrelor
US20120052058A1 (en) * 2010-08-30 2012-03-01 Emory University Methods of managing the blood coagulation and pharmaceutical compositions related thereto
AR082803A1 (es) * 2010-09-01 2013-01-09 Portola Pharm Inc Metodos y formulaciones para el tratamiento de la trombosis con betrixaban y un inhibidor de la glicoproteina p
TW201221128A (en) 2010-09-01 2012-06-01 Portola Pharm Inc Crystalline forms of a factor Xa inhibitor
US20140346397A1 (en) 2012-12-27 2014-11-27 Portola Pharmaceuticals, Inc. Compounds and methods for purification of serine proteases
US9200268B2 (en) 2012-12-27 2015-12-01 Portola Pharmaceuticals, Inc. Compounds and methods for purification of serine proteases
US10603316B2 (en) 2013-08-21 2020-03-31 Morehouse School Of Medicine Composition and methods for preventing or reducing the incidence of transient ischemic attacks
WO2015038968A1 (en) * 2013-09-13 2015-03-19 The General Hospital Corporation Activatable fibrin-binding probes
TW201613581A (en) * 2014-09-02 2016-04-16 Daiichi Sankyo Co Ltd Pharmaceutical composition for suppression of thromboembolization after stent placement
WO2017091757A1 (en) 2015-11-24 2017-06-01 Portola Pharmaceuticals, Inc. Isotopically enriched betrixaban
US20190300483A1 (en) * 2016-06-02 2019-10-03 Dr. Reddy's Laboratories Limited POLYMORPHS OF BETRlXABAN & ITS MALEATE SALT
CN110740736A (zh) 2017-06-23 2020-01-31 奇斯药制品公司 预防体-肺动脉分流术血栓形成的方法
WO2020047097A1 (en) * 2018-08-28 2020-03-05 Morehouse School Of Medicine Composition and methods for preventing or reducing the incidence of transient ischemic attacks
CN116782911A (zh) * 2020-09-17 2023-09-19 艾克赛特赫拉制药有限责任公司 治疗性化合物、组合物及其使用方法
EP4070658A1 (de) * 2021-04-06 2022-10-12 BIORoxx GmbH Verwendung von blutgerinnungshemmenden verbindungen als rodentizide

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUT76346A (en) 1994-04-26 1997-08-28 Selectide Corp Factor xa inhibitors
ES2216625T3 (es) * 1998-11-27 2004-10-16 ABBOTT GMBH & CO. KG Bencimidazoles substituidos y su empleo como inhibidores de parp.
US6794412B1 (en) * 1999-03-11 2004-09-21 Bristol-Myers Squibb Pharma Company Treatment of thrombosis by combined use of a factor Xa inhibitor and aspirin
JP4744050B2 (ja) * 1999-09-17 2011-08-10 ミレニアム・ファーマシューティカルズ・インコーポレイテッド ベンズアミドおよび関連するＸａ因子阻害剤
US6844367B1 (en) * 1999-09-17 2005-01-18 Millennium Pharmaceuticals, Inc. Benzamides and related inhibitors of factor Xa
BR0014078A (pt) * 1999-09-17 2002-12-31 Millennium Pharm Inc Inibidores de fator xa
US6376515B2 (en) 2000-02-29 2002-04-23 Cor Therapeutics, Inc. Benzamides and related inhibitors of factor Xa
GB0013407D0 (en) * 2000-06-02 2000-07-26 Astrazeneca Ab Forms of a chemical compound
US7235567B2 (en) 2000-06-15 2007-06-26 Schering Corporation Crystalline polymorph of a bisulfate salt of a thrombin receptor antagonist
US20040192753A1 (en) 2000-06-15 2004-09-30 Samuel Chackalamannil Methods of use of thrombin receptor antagonists
US7312043B2 (en) * 2000-07-10 2007-12-25 Vertex Pharmaceuticals (San Diego) Llc Ion channel assay methods
US6511973B2 (en) 2000-08-02 2003-01-28 Bristol-Myers Squibb Co. Lactam inhibitors of FXa and method
HRP20000765A2 (en) 2000-11-10 2002-06-30 Pliva D D Compositions of n-(1-methylethylaminocarbonyl)-4-(3-methylphenylamino)-3-pyridylsulfonamide and cyclic oligosaccharides with increased release
DE10065475A1 (de) * 2000-12-28 2002-07-18 Switch Biotech Ag Verwendung von "intermediate-conductance" Kaliumkanälen und Modulatoren zur Diagnose und Behandlung von Krankheiten mit gestörter Keratinozytenfunktion
AU2002258394A1 (en) * 2001-02-07 2002-09-12 Bristol-Myers Squibb Company Polynucleotide encoding a novel human potassium channel beta-subunit, k+betam3
US7312235B2 (en) * 2001-03-30 2007-12-25 Millennium Pharmaceuticals, Inc. Benzamide inhibitors of factor Xa
US20030129193A1 (en) * 2001-09-27 2003-07-10 Board Of Regents, The University Of Texas System And Peregrine Pharmaceuticals, Inc. Combined methods for tumor vasculature coaguligand treatment
US7030141B2 (en) 2001-11-29 2006-04-18 Christopher Franklin Bigge Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade
FR2838057B1 (fr) * 2002-04-05 2005-07-08 Servier Lab Nouvelle association d'un antithrombotique et d'aspirine
US20040067995A1 (en) * 2002-10-02 2004-04-08 Wong Pancras C. Novel combination of a factor Xa inhibitor and clopidogrel
EP1663239A4 (en) * 2003-09-10 2008-07-23 Cedars Sinai Medical Center KALIUM CHANNEL-MEDIATED FEEDING OF MEDICINES BY THE BLOOD BRAIN BARRIER
FR2860436B1 (fr) * 2003-10-03 2006-01-20 Servier Lab Nouvelle association d'un anti-atherothrombotique et d'un antiagregant plaquettaire
US7022695B2 (en) * 2003-10-09 2006-04-04 Millennium Pharmaceuticals, Inc. Thioether-substituted benzamides as inhibitors of Factor Xa
DE102004016845A1 (de) * 2004-04-07 2005-10-27 Bayer Healthcare Ag Phenylthioessigsäure-Derivate und ihre Verwendung
US7521470B2 (en) * 2004-06-18 2009-04-21 Millennium Pharmaceuticals, Inc. Factor Xa inhibitors
US7696352B2 (en) * 2004-06-18 2010-04-13 Millennium Pharmaceuticals, Inc. Factor Xa inhibitors
DE102004046623A1 (de) * 2004-09-25 2006-03-30 Bayer Healthcare Ag Neue Pyrimidin-Derivate und ihre Verwendung
DE102005027150A1 (de) * 2005-03-12 2006-09-28 Bayer Healthcare Ag Pyrimidincarbonsäure-Derivate und ihre Verwendung
JPWO2006137510A1 (ja) * 2005-06-24 2009-01-22 小野薬品工業株式会社 脳血管障害時における出血低減剤
CN102336702B (zh) * 2005-11-08 2015-02-11 米伦纽姆医药公司 Xa因子抑制剂n-(5-氯-2-吡啶基)-2-[[4-[(二甲氨基)亚氨基甲基]苯甲酰基]氨基]-5-甲氧基-苯甲酰胺的医药盐和多晶型
WO2007112367A2 (en) 2006-03-27 2007-10-04 Portola Pharmaceuticals, Inc. Potassium channel modulators and platelet procoagulant activity
EP2016072B1 (en) 2006-05-05 2014-07-16 Millennium Pharmaceuticals, Inc. Factor xa inhibitors
CN101595092B (zh) * 2006-11-02 2012-02-01 米伦纽姆医药公司 合成因子xa抑制剂的医药盐的方法
EP2101760B1 (en) * 2006-12-08 2013-02-27 Millennium Pharmaceuticals, Inc. Unit dose formulations and methods of treating thrombosis with an oral factor xa inhibitor
JP2010515691A (ja) * 2007-01-05 2010-05-13 ミレニアム・ファーマシューティカルズ・インコーポレイテッド 第Ｘａ因子阻害剤
KR101509829B1 (ko) * 2007-05-02 2015-04-06 포톨라 파마슈티컬스, 인코포레이티드 혈소판 ａｄｐ 수용체 억제제로 작용하는 화합물을 이용한 병용요법

Also Published As

Publication number Publication date
US20080254036A1 (en) 2008-10-16
MX2009010953A (es) 2009-10-29
CA2683793A1 (en) 2008-10-23
CN103071154A (zh) 2013-05-01
GT200900260A (es) 2011-09-05
EP2155195A2 (en) 2010-02-24
BRPI0809655B8 (pt) 2021-05-25
EA200970946A1 (ru) 2010-04-30
EP2155195B1 (en) 2014-07-16
US20120046230A1 (en) 2012-02-23
AU2008239659A1 (en) 2008-10-23
US8455440B2 (en) 2013-06-04
WO2008127682A2 (en) 2008-10-23
WO2008127682A3 (en) 2009-05-07
BRPI0809655A2 (pt) 2014-10-07
EA020531B1 (ru) 2014-11-28
TN2009000408A1 (en) 2011-03-31
HK1141230A1 (en) 2010-11-05
KR101473207B1 (ko) 2014-12-16
KR20100016428A (ko) 2010-02-12
DOP2009000244A (es) 2010-02-28
CN101743001B (zh) 2013-02-06
EP2591783A1 (en) 2013-05-15
NZ580162A (en) 2012-10-26
IL201433A (en) 2016-02-29
IL201433A0 (en) 2010-05-31
JP2010523679A (ja) 2010-07-15
US20130315897A1 (en) 2013-11-28
BRPI0809655B1 (pt) 2019-09-10
JP2013177459A (ja) 2013-09-09
AU2008239659B2 (en) 2013-09-05
CA2683793C (en) 2016-09-20
CN101743001A (zh) 2010-06-16

Similar Documents

Publication Publication Date Title
JP5469595B2 (ja) 第Ｘａ因子阻害薬として作用する化合物との併用抗凝固療法
JP2010523679A5 (enExample)
JP5439363B2 (ja) 血小板ａｄｐ受容体阻害剤として作用する化合物による併用療法
JP2013536220A (ja) 血栓症または塞栓を治療または予防するための方法
JP2013536230A (ja) 抗凝固療法を受けている哺乳動物における高血圧の治療および／または心不全の予防もしくは治療
EP2062580A1 (en) Use of dipyridamole or mopidamole for treatment and prevention of thromboembolic diseases and disorders caused by excessive formation of thrombin and/or by elevated expression of trombin receptors
CN100577170C (zh) 吡唑并嘧啶类Src家族酪氨酸激酶抑制剂在制备治疗心肌梗死的药物中的应用
KR20190064686A (ko) 혈액 응고를 저해하는 화합물들의 살서제로서의 사용
HK1141230B (en) Combination anticoagulant therapy with a compound that acts as a factor xa inhibitor
JP2022506548A (ja) 化合物の抗ｐｃｓｋ９（抗プロタンパク質変換酵素スブチリシン ケキシン９型）ナノ製剤および心血管疾患の治療および／または予防におけるその使用方法
TW200403988A (en) Use of inhibitors of the sodium/hydrogen exchanger for the treatment of thrombotic and inflammatory disorders
CN116782911A (zh) 治疗性化合物、组合物及其使用方法
US20230218594A1 (en) Therapeutic compounds, compositions, and methods of use thereof
TW202404601A (zh) 用於選擇性消退血栓性或血栓栓塞性疾病中血栓的凝乳酶抑制劑
CA2720278A1 (en) Agent for preventing and/or treating vascular diseases
HK40117115A (zh) 用於血栓性或血栓栓塞性病症中血栓的选择性溶解的糜蛋白酶抑制剂
MX2015002646A (es) Otamixaban para uso en el tratamiento de sindrome coronario agudo sin elevacion de st en pacientes programados para ser sometidos a injerto de bypass de arteria coronaria.
JP2007238609A (ja) 糖尿病患者における虚血性疾患の予防のための医薬
CN101023936A (zh) 预防糖尿病患者的缺血性疾病的医药

Legal Events

Date Code Title Description
A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20110324

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110324

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120313

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130318

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130618

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20140117

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20140131

R150 Certificate of patent or registration of utility model

Ref document number: 5469595

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees